🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cangzhou
Clinical trial register · China

Clinical Trials in Cangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 Peking Union Medical College Hospital6 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Novo Nordisk A/S2 Daiichi Sankyo2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Cangzhou

60 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Cohort Study of Perioperative Ultrasound and Delirium Following Hip Surgery
NCT07820007Hip Orthopaedic
Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
Observational
620
Cangzhou
2026-09-20
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
DrugRecaticimab
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Not yet open
Guided Laminectomy With Augmented Duroplasty for Acute Traumatic Spinal Cord Injury
NCT07733401Spinal Cord Injury, Acute Spinal Cord Injury (SCI)
Xuanwu Hospital, Beijing
Not applicable
80
Beijing, Guangzhou, Maoming, Cangzhou, Shijiazhuang, Chifeng, Dezhou, Jinan
2026-09
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugAZD6234
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-21
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugAZD6234
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Recruiting
Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis
NCT07711262Seasonal Allergic Rhinitis
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.
Phase 3
550
Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Baotou, Chifeng, Yinchuan, Jinan
2026-08-18
Recruiting
Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis
NCT07678931Seasonal Allergic Rhinitis (SAR)
DrugStapokibart
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Not yet open
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-08-01
Not yet open
Bionic Balloon-assisted Delivery Technology on the Labor Process
NCT07707804Vaginal Delivery
Peking Union Medical College Hospital
Not applicable
300
Cangzhou, Beijing
2026-07-15
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
800
Baotou, Binzhou, Cangzhou, Changsha, Chengdu, Ganzhou, Haikou, Hangzhou
2026-07-06
Recruiting
Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective, Multicenter, Single-Group Target Value Study
NCT07453381Coronary Microvascular Dysfunction (CMD)
Peking University Third Hospital
Observational
114
Beijing, Cangzhou, Chengdu
2026-06-30
Not yet open
Artificial Intelligence for Rare Disease Diagnosis
NCT07625436Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
150
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-06-20
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Recruiting
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
NCT07516184Suspected Asthma
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Active, closed
LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia
NCT07350486Hypertension, Diabetes, Dyslipidemia
First Hospital of China Medical University
Not applicable
6,800
Cangzhou, Suzhou, Panjin, Shenyang, Jinzhou, Tianjin
2026-05-14
Recruiting
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT07520162Chronic Rhinosinusitis With Nasal Polyps
DrugTezepelumab
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Foshan
2026-04-24
Recruiting
Smartwatch-based Intervention for Cardiovascular Health (SWITCH)
NCT07372729Prehypertension, Borderline Dyslipidemia, Overweight , Obesity, Prediabetes
Beijing Anzhen Hospital
Not applicable
1,400
Beijing, Cangzhou, Yuhuan
2026-03-24
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Cangzhou, Kaifeng, Xuzhou, Zhenjiang, Xianyang, Jinan, Ningbo, Beijing
2026-03-23
Recruiting
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
NCT07398859Seasonal Allergic Rhinitis
DrugTQH2722
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Recruiting
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.
NCT07658534Respiratory Syncytial Virus Infections
DrugZiresovir
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 2/3
290
Beijing, Guangzhou, Cangzhou, Nanyang, Zhengzhou, Wuhan, Hangzhou, Rui’an
2026-03-03
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529Advanced Lung Cancer
DrugTQB6411
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
DrugTenecteplase
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsHLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
NCT07304739Non Small Cell Lung Cancer
DrugFurmonertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Cangzhou, Tianjin
2025-12-22
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493Acute Ischemic Stroke
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Active, closed
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
NCT06890533Pain
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Ch’ang-ch’un, Dalian, Deyang
2025-05-14
Not yet open
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929Prostate Cancer Recurrent
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06789289Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
256
Hefei, Beijing, Chongqing, Foshan, Jiangmen, Liuzhou, Yulin, Cangzhou
2025-03-17
Recruiting
Modified Tumor-free Techniques Operation to Cervical Cancer
NCT06836869Cervical Cancer Stage IB2
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Recruiting
Normobaric Oxygen in AIS Transferred for EVT
NCT06666764Ischemic Stroke
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Carboplatin
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Recruiting
Comparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI)
NCT06429774Traumatic Brain Injury
Beijing Tiantan Hospital
Observational
2,000
Beijing, Baoding, Cangzhou, Chengde, Handan, Langfang, Qinhuangdao, Shijiazhuang
2024-08-01
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
DrugB001
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Hyperplasia of Mammary Glands
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
NCT06122831Myelofibrosis
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Anastrozole·Exemestane
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Hefei, Beijing, Dongguan, Guangzhou, Cangzhou, Changsha, Nanjing, Nanchang
2023-05-20
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 3
1,170
Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-01-11
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Pembrolizumab
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-08-14
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Recruiting
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
NCT06534658Alzheimer Disease, Image
Ruijin Hospital
Observational
1,000
Beijing, Hanzhong, Cangzhou, Shijiazhuang, Qingdao, Shanghai, Shenyang
2020-07-30
Rows per page Showing 1–60 of 60
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/cangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 60 of those studies with a site in Cangzhou.

How many clinical trials are recruiting in Cangzhou?

36 of the 60 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 13 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cangzhou), 60 studies
PhaseStudiesRecruitingShare
Phase 3281346.7%
Not applicable10516.7%
Phase 27611.7%
Observational6510%
Phase 1/2335%
Phase 1213.3%
Phase 2/3223.3%
Phase 4213.3%

Most active sponsors

Lead sponsors with the most studies (Cangzhou)
Lead sponsorStudiesRecruiting
AstraZeneca75
Peking Union Medical College Hospital62
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.33
Beijing Tiantan Hospital22
Betta Pharmaceuticals Co., Ltd.22
Daiichi Sankyo20
Novo Nordisk A/S21
Shanghai Henlius Biotech21
Tianjin Medical University Cancer Institute and Hospital22
Yunhe Pharmaceutical (Tianjin) Co., Ltd20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.